







## EUROPEAN RESPIRATORY journal

FLAGSHIP SCIENTIFIC JOURNAL OF ERS



# Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation

Ivan Solovic, Alena Bodnarova, Laurent Morin European Respiratory Journal 2020 56: 952; **DOI:** 10.1183/13993003.congress-2020.952

Article

Info & Metrics

### **Abstract**

**Introduction:** Airway clearance devices (ACDs) may improve symptoms and lung function in Chronic Obstructive Pulmonary Disease (COPD) with mucus hyperproduction or bronchiectasis but innovation needs to be evaluated.

**Aim:** Aim of study was to assess feasibility and effects of a new ACD in hospitalized COPD patients suffering from chest congestion despite optimal medical treatment.

**Methods:** 32 patients with AECOPD and symptoms of excessive mucus congestion were treated during 6 days with medical treatment, pulmonary rehabilitation and airway clearance with either manual chest physiotherapy (control; n=13) or new ACD (Simeox, Physio-Assist; n=19) that facilitates bronchial drainage by generating pulses of negative air pressure during relaxed exhalations. Usability, spirometry, CAT score, safety and tolerance were evaluated.

**Results:** Baseline: age 67.3 6.7, 69% male, GOLD 2/3/4: 19%/31%/50%, GOLD B/C/D: 3%/19%/78%, 31% bronchiectasis (BE), 66% had ICS/LABA/LAMA, CAT score 29.0±3.3.

Patient training required 15 min during the first session. No adverse event nor pain was reported. FEV1 increased by 19±10% and 14±5% in device and control group (NS), respectively. However, improvement of CAT score was higher in device group (-34±9% vs control: -24±4%; p<0.001). FEV1 increase was higher in very

severe COPD treated with device ( $\pm 24\pm 10\%$  vs control:  $\pm 15\pm 5\%$ , p<0.05). COPD with bronchiectasis benefited the most from device therapy (FEV1:  $\pm 28\pm 6\%$ , CAT  $\pm 38\pm 9\%$ ).

**Conclusion:** These results confirmed the feasibility of this new technology to manage mucus problems in COPD and suggested that it may contribute to improve respiratory symptoms and quality of life in the most severe patients

**Bronchiectasis** 

COPD - management

Physiotherapy care

#### **Footnotes**

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 952.

This abstract was presented at the 2020 ERS International Congress, in session "Respiratory viruses in the "pre COVID-19" era".

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Copyright ©the authors 2020

### We recommend

Late Breaking Abstract - Effects of a new Airway Clearance Technology versus manual physiotherapy in COPD

Florin Mihaltan et al., European Respiratory Journal, 2018

Feasibility and safety evaluation of Simeox airway clearance technique (ACT) in patients with bronchiectasis

Vitezslav Kolek et al., European Respiratory Journal, 2019

Late Breaking Abstract - Benefits of a low-frequency airway clearance technology in non-CF patients with bronchiectasis

Katarzyna Iwan et al., European Respiratory Journal, 2018

Impacts of bronchiectasis in asthma patients with airflow limitation

Natsuko Nomura et al., European Respiratory Journal

Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease

Nicolai Obling et al., European Respiratory Journal, 2020

M24 Validation of the COPD assessment test (CAT) as an outcome measure in bronchiectasis

S Finch et al., Thorax, 2019

Effect of leukotriene receptor antagonists (LTRAs) on airway inflammation in patients with asthma-COPD overlap (ACO) and its mechanism

LIU Mei-xuan et al., Fudan University Journal of Medical Sciences, 2018

COPD assessment test for the evaluation of COVID-19 symptoms

Enya Daynes et al., Thorax, 2020

Quality of survival and adverse events in nonmetastatic castration-resistant prostate cancer: what are patients' and caregivers' preferences? Sandy Srinivas et. al, Cancer Medicine, 2020

THU0616-HPR EXPIRATORY FLOW ACCELERATOR (EFA) IN SYSTEMIC SCLEROSIS PATIENTS WITH MUCUS HYPERSECRETION, PRODUCTIVE COUGH AND DYSPNOEA: PRELIMINARY RESULTS FROM A HOME-BASED

AIRWAY CLEARANCE TECHNIQUE DAILY PROGRAM

S. Faverzani et al., Ann Rheum Dis, 2020